---
title: The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion
nct_id: NCT02068560
overall_status: COMPLETED
phase: NA
sponsor: University of Aarhus
study_type: INTERVENTIONAL
primary_condition: Gender Difference in V2 Receptor Function in Response to dDAVP Infusion
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02068560.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02068560"
ct_last_update_post_date: 2014-12-11
last_seen_at: "2026-05-12T06:55:15.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion

**NCT ID:** [NCT02068560](https://clinicaltrials.gov/study/NCT02068560)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 64
- **Lead Sponsor:** University of Aarhus
- **Collaborators:** Ferring Pharmaceuticals
- **Conditions:** Gender Difference in V2 Receptor Function in Response to dDAVP Infusion, Nocturia, Nocturnal Enuresis
- **Start Date:** 2012-05
- **Completion Date:** 2014-12
- **CT.gov Last Update:** 2014-12-11

## Brief Summary

There is substantial evidence that women throughout life have significantly lower plasma levels of the antidiuretic hormone vasopressin (pAVP) compared to men. The importance of this is not yet fully elucidated, but in relation to the observations of lower pAVP levels, no significant difference in renal response parameters was found. This could be interpreted an increased renal sensitivity in females compared to males. The theory of increased renal sensitivity in females is supported by a few pharmacodynamic studies currently available on this topic. However none of the studies was designed with the purpose of investigate the gender difference.

The aim of this study is to investigate possible gender differences in the renal sensitivity to dDAVP and the effect of age on these differences. This will be done by low dose graded infusion of the synthetic AVP analog dDAVP.

Participants are 80 healthy volunteers equally distributed between four age groups, 8-10 years of age, 16-18 years of age, 25-40 years og age and 65+ years of age.

## Eligibility

- **Minimum age:** 8 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy
* Normal clinical examination
* Normal residual urine measurements
* Normal urine dip stick
* Informed consent by participant or legal guardian

Exclusion Criteria:

* Smoking, alcohol or drug abuse
* Conditions of importance to the results (endocrinological, renal or cardial)
* Current or previous history of incontinence, bedwetting or nocturia
* Drug use of importance (diuretics, hormone replacement therapy, birth control pills, desmopressin)
* Pregnancy
* Allergy towards dDAVP/desmopressin
```

## Arms

- **dDAVP infusion** (EXPERIMENTAL) — During the 9 hour study period, the subjects will receive three doses of dDAVP infusion (0.0003micrg/kg, 0.0005micrg/kg, 0.004micrg/kg).

## Interventions

- **dDAVP infusion** (DRUG)

## Primary Outcomes

- **Urine osmolality** _(time frame: Samples for urine osmolality is measured every half hour throughout the 9 hour study period and measured the following day)_
- **Urine Volume** _(time frame: Urine Volume is measured every half hour throughout the 9 hours study period)_
- **Plasma dDAVP** _(time frame: Plasma concentrations of the synthetic hormone is measured every 90 minutes for the first 8 hours and every half hour, the last hour of the study period)_

## Secondary Outcomes

- **Plasma sodium** _(time frame: Plasma sodium is measured every 90 minutes throughout the first 8 hours and every half hour in the last hour of the study periode)_

## Locations (1)

- Aarhus University Hospital, Aarhus, Denmark

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `locations.aarhus university hospital|aarhus||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02068560.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02068560*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*